|
π’
|
Voriconazole treatment for less-common, emerging, or refractory fungal infections.
11 auth.
J. Perfect,
K. Marr,
T. Walsh,
R. Greenberg,
B. Dupont,
J. de la Torre-Cisneros,
...
G. Just-NuΜbling,
H. Schlamm,
I. Lutsar,
A. Espinel-Ingroff,
Elizabeth Johnson
|
9 |
2003 |
9
π’
|
|
π¬
|
Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
A. Espinel-Ingroff,
Elizabeth Johnson,
H. Hockey,
P. Troke
|
6 |
2008 |
6
π¬
|
|
π
|
Low Effective Dispersal of Asexual Genotypes in Heterogeneous Landscapes by the Endemic Pathogen Penicillium marneffei
7 auth.
M. Fisher,
W. Hanage,
S. de Hoog,
Elizabeth Johnson,
Michael D. Smith,
N. White,
...
N. Vanittanakom
|
5 |
2005 |
5
π
|
|
π
|
Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal Meningitis
9 auth.
A. Brouwer,
H. J. V. van Kan,
Elizabeth Johnson,
A. Rajanuwong,
P. Teparrukkul,
V. Wuthiekanun,
...
W. Chierakul,
N. Day,
T. Harrison
|
5 |
2006 |
5
π
|
|
π
|
Fungal infections in patients with cystic fibrosis
7 auth.
Y. Nagano,
B. Millar,
Elizabeth Johnson,
C. Goldsmith,
J. Elborn,
J. Rendall,
...
J. Moore
|
5 |
2007 |
5
π
|
|
π¬
|
Posaconazole Therapy of Disseminated Phaeohyphomycosis in a Murine Model
J. Graybill,
L. Najvar,
Elizabeth Johnson,
R. Bocanegra,
D. Loebenberg
|
5 |
2004 |
5
π¬
|
|
π¦
|
Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Elizabeth Johnson,
A. Espinel-Ingroff,
A. SzΓ©kely,
H. Hockey,
P. Troke
|
5 |
2008 |
5
π¦
|
|
π¬
|
Sternal Wound Infection by Trichosporon inkin following Cardiac Surgery
F. Davies,
S. Logan,
Elizabeth Johnson,
J. Klein
|
3 |
2006 |
3
π¬
|
|
π¬
|
R2284 Aspergillus endophthalmitis in an immunocompetent woman: intra-ocular penetration of oral voriconazole
S. Logan,
E. Graham,
M. Rajan,
Elizabeth Johnson,
J. Klein
|
0 |
2007 |
0
π¬
|
